Skip to main content

Table 3 Numbers of total, proliferative and apoptotic CTCs in serial samples during the dormancy period for DC with late relapse (n = 8)

From: Evaluation of proliferation and apoptosis markers in circulating tumor cells of women with early breast cancer who are candidates for tumor dormancy

Patient number Dormancy period (yrs) Test no/(time since surgery yrs) Status Total CTCs Dormant a/Total (%) Nondormant d/Total (%) Proliferative b/Nondormant d(%) Apoptotic c/Nondormant d(%)
1 6 1/3 (5y) DF 1 100 0 0 0
2/3 (5.5y) DF 4 87.5 12.5 100 0
   3/3 (6y) R 3 83.3 16.7 100 0
2 7 1/4 (5y) DF 12 50 50 100 0
2/4 (5.5y) DF 215 93 7 80 20
3/4 (6.5y) DF 2 50 50 100 0
   4/4 (7y) R 1 0 0 100 0
3 10.5 1/5 (5.5y) DF 0 0 0 0 0
2/5 (6y) DF 0 0 0 0 0
3/5 (8y) DF 22 50 50 36.4 63.6
4/5 (10y) DF 0 0 0 0 0
   5/5 (10.5y) R 0.5 100 0 0 0
4 9.5 1/5 (5y) DF 1 100 0 0 0
2/5 (5.5y) DF 9 89 11 0 100
3/5 (6.5y) DF 57 91.3 8.7 20 80
4/5 (7.5y) DF 1 100 0 0 0
   5/5 (9.5y) R 0 0 0 0 0
5 11 1/4 (5y) DF 9.5 100 0 0 0
2/4 (6y) DF 38 87.3 12.7 3.5 96.5
3/4 (10y) DF 0 0 0 0 0
   4/4 (11y) R 0 0 0 0 0
6 10.5 1/7 (5.5y) DF 0 0 0 0 0
2/7 (7y) DF 0 0 0 0 0
3/7 (7.5y) DF 0 0 0 0 0
4/7 (8y) DF 0 0 0 0 0
5/7 (9y) DF 2.5 60 40 100 0
6/7 (10y) DF 0.5 100 0 0 0
   7/7 (10.5y) R 9 50 50 100 0
7 15 1/3 (11y) DF 5 100 0 0 0
2/3 (12y) DF 2 100 0 0 0
   3/3 (15y) R 0.5 100 0 0 0
8 11 1/4 (6.5y) DF 0 0 0 0 0
2/4 (7y) DF 0 0 0 0 0
3/4 (7.5y) DF 1 100 0 0 0
   4/4 (11y) R 0.5 100 0 0 0
  1. aKi67(-)/M30(-) CTCs, bKi67(+)/M30(-) CTCs, cKi67(-)/M30(+), dKi67(+)/M30(-) or Ki67(-)/M30(+) CTCs. CTCs, circulating tumor cells; DC, dormancy candidates; DF, disease-free; R, on relapse.